JATT Acquisition Corp
JATT-WT
New York Stock Exchange0.29
USD
-0.05
- -
JATT Acquisition Corp
JATT-WT
(New York Stock Exchange)
Recent
price
0.29
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- JATT Acquisition Corp (NYSE: JATT-WT) serves as a blank check company, or special purpose acquisition company (SPAC), with no substantial independent operations and focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting those operating in the life sciences sector; it offers redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share, which trade separately under the ticker JATT-WT following the separation from its units (NYSE: JATTU) that originally comprised one Class A ordinary share and one-half of one redeemable warrant. Incorporated in 2021 as a Cayman Islands exempted company, the firm maintains its headquarters at Ugland House, PO Box 309, Grand Cayman, KY1-1104, Cayman Islands, and its team comprises biotechnology entrepreneurs and pharmaceutical industry veterans, including Founder and CEO Dr. Someit Sidhu, who also serves as a director alongside other founders like Tauhid Ali, PhD, Graeme Sloan, and Verender S. Badial, supported by advisors from Novartis, Sanofi Genzyme, and Pfizer. In March 2023, JATT shareholders approved and completed a reverse merger business combination with Zura Bio Limited, a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases including assets like ZB-168 and torudokimab, resulting in the combined entity renaming to Zura Bio Limited (NASDAQ: ZURA, ZURAW) with an initial enterprise value of approximately $215 million and gross proceeds of up to $189 million from trust funds, PIPE financing, and forward purchase agreements; post-merger, JATT's original Class A shares and warrants ceased NYSE listing on March 20, 2023, while JATT-WT warrants persist as legacy securities exercisable into Zura Bio ordinary shares subject to merger terms and customary closing conditions.